Biology and Management of Multiple Myeloma (Current Clinical Oncology)
Published: Oct 15, 2008 8:00 am
|
Editor: James R. Berenson Book Description: Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi’s sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents. |
Related Articles:
- Addition Of Velcade To Revlimid-Dexamethasone May Yield Better Prognosis For Myeloma Patients With Certain Chromosomal Abnormalities
- Certain Chromosomal Abnormalities Negatively Impact The Outcome Of Revlimid-Dexamethasone Therapy In Relapsed And Refractory Multiple Myeloma Patients
- Tools For Diagnosing Multiple Myeloma / Part 3: Prognostic Evaluation
- Detection Of Rapidly Dividing Plasma Cells May Lead To More Targeted Treatment For Multiple Myeloma Patients
- M-CSF May Act As Powerful Prognostic Factor For Multiple Myeloma
Leave a comment